Digital health company Liva Healthcare has acquired UK-based Momenta, a provider of digital, virtual, and in-person healthy ...

We took advantage of price dislocations in several leading growth franchises to enhance our health care and consumer discretionary ... to portfolio holding Eli Lilly (LLY) due to delays in scaling ...

The Charlotte Hornets filled the Spectrum Center lobby, assembling 3,000 care kits for U.S. service members Tuesday. It’s an event the organization has held for 11 years. ALSO READ: Hornets ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful ... For the past year, Jonsson has run Lilly Diabetes and Obesity, which means he oversees ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large-cap value stocks. The market outlook is as uncertain as it gets. On January 18 ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

The letter follows Bloomberg’s reporting last week that drugmakers including Eli Lilly & Co. are planning ... including best-selling diabetes and weight-loss medications Ozempic and Wegovy.

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $725.72. According to ...

Shares of Eli Lilly & Co. were headed for their worst ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...